{"id":919813,"date":"2025-12-15T16:04:41","date_gmt":"2025-12-15T21:04:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/"},"modified":"2025-12-15T16:04:41","modified_gmt":"2025-12-15T21:04:41","slug":"monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/","title":{"rendered":"Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1\/2 Study Results"},"content":{"rendered":"

\nConference call and webcast to be held at 8 a.m. ET on December 16, 2025
\n<\/h2>\n
\n

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc.<\/u><\/a> (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on\u00a0Tuesday, December 16, 2025, at\u00a08:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1\/2 study of the GSPT1-directed MGD MRT-2359 in heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC) patients.<\/p>\n

A webcast of the presentation will be accessible via the \u201cEvents & Presentations\u201d section of Monte Rosa\u2019s website at\u00a0ir.monterosatx.com<\/a>. Registration for the conference call is available at the following link<\/a>. An archived version of the webcast will be made available for 30 days following the presentation.<\/p>\n

\n About Monte Rosa<\/strong>
\n
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa\u2019s QuEEN\u2122 (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry\u2019s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology. For more information, visit www.monterosatx.com<\/a>.<\/p>\n

\n Investors<\/strong>
\n
Andrew Funderburk
ir@monterosatx.com<\/u><\/a><\/p>\n

\n Media<\/strong>
\n
Cory Tromblee, Scient PR
media@monterosatx.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Conference call and webcast to be held at 8 a.m. ET on December 16, 2025 BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on\u00a0Tuesday, December 16, 2025, at\u00a08:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1\/2 study of the GSPT1-directed MGD MRT-2359 in heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC) patients. A webcast of the presentation will be accessible via the \u201cEvents & Presentations\u201d section of Monte Rosa\u2019s website at\u00a0ir.monterosatx.com. Registration for the conference call is available at the following link. An archived version of … <\/p>\n

Continue reading “Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1\/2 Study Results”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-919813","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMonte Rosa Therapeutics to Present Updated MRT-2359 Phase 1\/2 Study Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1\/2 Study Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Conference call and webcast to be held at 8 a.m. ET on December 16, 2025 BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on\u00a0Tuesday, December 16, 2025, at\u00a08:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1\/2 study of the GSPT1-directed MGD MRT-2359 in heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC) patients. A webcast of the presentation will be accessible via the \u201cEvents & Presentations\u201d section of Monte Rosa\u2019s website at\u00a0ir.monterosatx.com. Registration for the conference call is available at the following link. An archived version of … Continue reading "Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1\/2 Study Results"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-15T21:04:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjMyNSM3MzIyMDI1IzIyMDk1NDU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1\\\/2 Study Results\",\"datePublished\":\"2025-12-15T21:04:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\\\/\"},\"wordCount\":283,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMjMyNSM3MzIyMDI1IzIyMDk1NDU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\\\/\",\"name\":\"Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1\\\/2 Study Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMjMyNSM3MzIyMDI1IzIyMDk1NDU=\",\"datePublished\":\"2025-12-15T21:04:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMjMyNSM3MzIyMDI1IzIyMDk1NDU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMjMyNSM3MzIyMDI1IzIyMDk1NDU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1\\\/2 Study Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1\/2 Study Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/","og_locale":"en_US","og_type":"article","og_title":"Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1\/2 Study Results - Market Newsdesk","og_description":"Conference call and webcast to be held at 8 a.m. ET on December 16, 2025 BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on\u00a0Tuesday, December 16, 2025, at\u00a08:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1\/2 study of the GSPT1-directed MGD MRT-2359 in heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC) patients. A webcast of the presentation will be accessible via the \u201cEvents & Presentations\u201d section of Monte Rosa\u2019s website at\u00a0ir.monterosatx.com. Registration for the conference call is available at the following link. An archived version of … Continue reading \"Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1\/2 Study Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-15T21:04:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjMyNSM3MzIyMDI1IzIyMDk1NDU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1\/2 Study Results","datePublished":"2025-12-15T21:04:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/"},"wordCount":283,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjMyNSM3MzIyMDI1IzIyMDk1NDU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/","name":"Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1\/2 Study Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjMyNSM3MzIyMDI1IzIyMDk1NDU=","datePublished":"2025-12-15T21:04:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjMyNSM3MzIyMDI1IzIyMDk1NDU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjMyNSM3MzIyMDI1IzIyMDk1NDU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-updated-mrt-2359-phase-1-2-study-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1\/2 Study Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=919813"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919813\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=919813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=919813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=919813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}